BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34217763)

  • 1. Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
    Kuperus JM; Busman RD; Kuipers SK; Broekhuizen HT; Noyes SL; Brede CM; Tobert CM; Lane BR
    Urology; 2021 Oct; 156():191-198. PubMed ID: 34217763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
    Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
    Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
    Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
    J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.
    Choi J; Kim KH; Kim HS; Yoon HS; Kim JH; Kim JW; Lee YS; Choi SY; Chang IH; Ko YH; Song W; Jeong BC; Nam JK
    Investig Clin Urol; 2024 May; 65(3):248-255. PubMed ID: 38714515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
    Haas CR; McKiernan JM
    Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
    Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
    Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
    J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
    Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
    Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Intravesical Therapy.
    Brooks NA; O'Donnell MA
    Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
    Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
    Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
    Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.